Banyan Biomarkers Announces U.S. Patent for Neural Proteins as
Biomarkers for Traumatic Brain Injury
ALACHUA, Fla. (Business Wire EON/PRWEB ) September 4, 2008 --
Banyan Biomarkers, Inc.
announced today that the U.S. Patent and Trademark Office has granted
U.S. Patent No. 7,396,654 B2 “Neural Proteins
as Biomarkers for Traumatic Brain Injury,”
licensed exclusively by Banyan Biomarkers from the University of
Florida. Specifically, the patent covers the detection of certain
neuronal protein markers found in the blood of patients suffering from
neural injury and / or neuronal damage. The patent also covers certain
sensitive and rapid methods and test kits that can be used as tools for
the diagnosis of neural injuries and/or neuronal disorders such as brain
injury, neural damage due to drug or alcohol addiction and diseases
associated with the brain and central nervous system.
Banyan Biomarkers also holds the exclusive license from the University
of Florida for U.S. Patent No. 7,291,710 “Detection
of spectrin and spectrin proteolytic cleavage products in assessing
nerve cell damage.”
Gary Ascani, Chief Executive Officer of Banyan Biomarkers, Inc.,
commented, “Banyan continues to effectively
build its intellectual property portfolio and broaden our applications
for biomarkers as critical tools for assisting physicians in diagnosing
and managing patients with traumatic brain injuries and other acute
central nervous system injuries such as stroke.”
Approximately 1.9 million traumatic brain injuries are sustained
annually. In a comparison provided by the Brain Injury Association of
America, more traumatic brain injuries occur annually than the combined
incidences of multiple sclerosis, spinal cord injuries, HIV/AIDS and
breast cancer.
Banyan Biomarkers is the leader in developing in vitro diagnostic
products to address unmet clinical needs for the detection of traumatic
brain injury. The company is focused on developing a simple
point-of-care blood test that will be used by physicians to detect the
presence and severity of brain trauma and facilitate the diagnosis and
management of head injured patients. Banyan Biomarkers also uses the
company’s proprietary biomarkers to provide
testing services for the pharmaceutical industry in the evaluation of
drug candidates for pre-clinical and clinical studies. To learn more
about Banyan Biomarkers, Inc., visit www.banyanbio.com
See the original story at: http://eon.businesswire.com/releases/biomarkers/banyan/prweb1289004.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1Db3VwLUhvcnItWmV0YS1QaWdnLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
